ArticlePloS one2011
Serological studies confirm the novel astrovirus HMOAstV-C as a highly prevalent human infectious agent.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.The Journal of clinical investigation · 2020Trial
- Unveiling the global urban virome through wastewater metagenomics.Nature communications · 2025Article
- Murine astrovirus infection course and antibody response in different mouse strains.Lab animal · 2025Article
- Novel murine model of human astrovirus infection reveals cardiovascular tropismJournal of virology · 2025Article
- High Seropositivity Rate of Neutralizing Antibodies to Astrovirus VA1 in Human Populations.mSphere · 2021Article
- Article
- Structural Insights into the Human Astrovirus Capsid.Viruses · 2021Review
- Beyond the Gastrointestinal Tract: The Emerging and Diverse Tissue Tropisms of Astroviruses.Viruses · 2021Review
- Epidemiology and Viral Etiology of Pediatric Immune Thrombocytopenia through Korean Public Health Data Analysis.Journal of clinical medicine · 2021Article
- Human Astroviruses: A Tale of Two Strains.Viruses · 2021Article
- Foodborne Viruses and Innovative Non-Thermal Food-Processing Technologies.Foods (Basel, Switzerland) · 2020Review
- Lethal Hemorrhagic Disease and Clinical Illness Associated with Elephant Endotheliotropic Herpesvirus 1 Are Caused by Primary Infection: Implications for the Detection of Diagnostic Proteins.Journal of virology · 2020Article
- Luciferase-Based Detection of Antibodies for the Diagnosis of HPV-Associated Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2019Article
- DifferentialmBio · 2019Article
- Characterizing a Murine Model for Astrovirus Using Viral Isolates from Persistently Infected Immunocompromised Mice.Journal of virology · 2019Article
- Infection and Propagation of Astrovirus VA1 in Cell Culture.Current protocols in microbiology · 2019Article
- Emerging technologies for the detection of viral infections.Future virology · 2019Article
- New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product.Emerging infectious diseases · 2018Article
- Astrovirus Infection and Diarrhea in 8 Countries.Pediatrics · 2018Article
- Propagation of Astrovirus VA1, a Neurotropic Human Astrovirus, in Cell Culture.Journal of virology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Molecular identification of a microbe is the first step in determining its prevalence of infection and pathogenic potential. Detection of specific adaptive immune responses can provide insights into whether a microbe is a human infectious agent and its epidemiology. Here we characterized human anti-IgG antibody responses by luciferase immunoprecipitation systems (LIPS) against two protein fragments derived from the capsid protein of the novel HMOAstV-C astrovirus. While antibodies to the N-terminal fragment were not informative, the C-terminal capsid fragment of HMOAstV-C showed a high frequency of immunoreactivity with serum from healthy blood donors. In contrast, a similar C-terminal capsid fragment from the related HMOAstV-A astrovirus failed to show immunoreactivity. Detailed analysis of adult serum from the United Sates using a standardized threshold demonstrated HMOAstV-C seropositivity in approximately 65% of the samples. Evaluation of serum samples from different pediatric age groups revealed that the prevalence of antibodies in 6-12 month, 1-2 year, 2-5 year and 5-10 year olds was 20%, 23%, 32% and 36%, respectively, indicating rising seroprevalence with age. Additionally, 50% (11/22) of the 0-6 month old children showed anti-HMOAstV-C antibody responses, likely reflecting maternal antibodies. Together these results document human humoral responses to HMOAstV-C and validate LIPS as a facile and effective approach for identifying humoral responses to novel infectious agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.